BLTE BELITE BIO INC

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss the Company’s financial results for the first half, ended June 30, 2022, and provide a corporate progress update. The financial results will be issued in a press release on Wednesday, August 10, 2022.

Belite Bio, Inc First Half 2022 Financial Result Conference Call Information:

Date:Thursday, August 11, 2022
Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Webcast Link:
Phone Registration Link:

Webcast Link Instructions

You can join a live webcast of the conference by visiting the “Webcast” link above or the “Presentations & Events” section of the Company’s Investor Relations website at . A reply will be available approximately two hours after the event for 30 days.

Phone Registration Instructions

To participate in the live call, please register using the “Phone Registration” link above. Once registered, you will receive dial-in numbers and unique PIN numbers via email. At the time of the call, you will dial in using the numbers from the confirmation email, and upon entering the unique PIN, will be routed into the call.

About Belite Bio

Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, such as atrophic age-related macular degeneration (commonly known as dry AMD) and Stargardt disease, and metabolic diseases. For more information, follow us the Company on , , , or visit us at .

Important Cautions Regarding Forward Looking Statements

This press release contains certain "forward-looking statements" within the meaning of federal securities laws. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about Belite’s beliefs and expectations. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in Belite’s filings with the U.S. Securities and Exchange Commission at . Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Media and Investor Relations Contact:

Jennifer Wu /

Tim McCarthy



EN
01/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation ...

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a three-month follow-up period)Tinlarebant has previously been granted Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and the Pioneer Drug Designation in Japan for Stargardt disease SAN DIEGO, May 21, 2...

 PRESS RELEASE

Belite Bio Reports First Quarter 2025 Financial Results and Provides C...

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)DSMB also recommended the Company submit the interim data for further regulatory review for drug approvalA pivotal global Phase 3 trial (PHOENIX) of Tinlarebant in geographic atrophy (GA) patient...

 PRESS RELEASE

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio to Participate in Four Upcoming Investor Conferences SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows: Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual) May 15, 2025, at 12:30 pm ET, corporate presentation H.C....

 PRESS RELEASE

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2...

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2025. Webcast InformationDate: Wednesday, ...

 PRESS RELEASE

Belite Bio Announces Poster Presentations at the Association for Resea...

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah. The presentations will hig...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch